Strategies for combination therapy in hypertension

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 5, 2012, Pages 486-491

  Gradman, Alan H ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antihypertensive therapy; combination therapy; pharmacological treatment

Indexed keywords

ALDOSTERONE; AMLODIPINE; ATENOLOL; AZILSARTAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDROCHLOROTHIAZIDE; LONG ACTING DRUG; OLMESARTAN; POTASSIUM; SPIRONOLACTONE; VALSARTAN;

AMBULATORY CARE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FUNCTION; LONG TERM CARE; MONOTHERAPY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; TREATMENT OUTCOME;

EID: 84865426582     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328356c551     Document Type: Review

References (31)

1. Chobanian AV, Bakris GL, Black HR, et al. National High Blood Pressure Education Program Coordinating Committee: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252. (Pubitemid 37553153)
2. Mancia G, DeBacker G, Dominiczak A, et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC): 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25:1105-1187. (Pubitemid 46924065)
3. Cushman WC, Ford CE, Einhorn PT, et al. Vidt DG, for the ALLHAT collaborative research group. Blood pressure control by drug group in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2008; 10:751-760.
4. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
5. Gradman AH. Rationale for triple combination therapy in the management of hypertension. J Clin Hypertens 2010; 12:869-878.
6. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326:1427-1435.
7. Neil B, MacMahon S, Chapman N. Effect of ACE inhibitors, calcium channel blockers, and other blood pressure lowering drugs: results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356:1955-1964.
8. Gradman AH, Basile JN, Carter BL, Bakris GL. ASH position paper: combination therapy in hypertension. J Am Soc Hypertens 2010; 4:90-98.
9. Chrysant SG. Antihypertensive therapy effectiveness of low-dose lisinoprilhydrochlorthiazide combination. A large multicenter study. Arch Intern Med 1994; 154:737-743. (Pubitemid 24115660)
10. Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005; 45:880-886. (Pubitemid 40628932)
11. Elliott W. Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. J Clin Hypertens 2009; 11:376-382.
12. Gradman AH, Cutler NR, Davis PJ, et al. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Am J Cardiol 1997; 79:431-435. (Pubitemid 127440407)
13. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120:713-719. (Pubitemid 47176510)
14. Lindholm L, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366:1545-1553. (Pubitemid 41540112)
15. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227-2236. (Pubitemid 39473160)
16. Munzel T, Gori T. Nebivolol: the somewhat different ß-adrenergic receptor blocker. J Am Coll Cardiol 2009; 54:1491-1499.
17. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
18. Jamerson K, Weber MA, Bakris GL, et al., for the ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
19. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006; 47:352-358. (Pubitemid 43740274)
20. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. JAMA 1967; 202: 116-121.
21. Flack JM, Sica DA, Nesbitt S. Chlorthalidone versus hydrochlorothiazide as the preferred diuretic: is there a verdict yeti Hypertension 2011; 57:665-666.
22. EDARBYCLOR (azilsartan medoxomil and chlorthalidone) package insert, Deerfield, IL: Takeda Pharmaceuticals America, Inc. 2011.
23. Calhoun DA, Lacourciere Y, Chiang YT, et al. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension 2009; 54:32-39.
24. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment-a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403-1419.
25. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16:925-930. (Pubitemid 37315491)
26. Weir M, Levy D, Crikelair N, et al. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens 2007; 20:807-815. (Pubitemid 46936176)
27. Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009; 53:646-653.
28. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363:2049-2051. (Pubitemid 38781107)
29. Corrao G, Nicotra F, Parodi A, et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension 2011; 58:566-572.
30. Gradman AH, Parise H, Lafeuille MH, et al. Impact of initial combination therapy vs. monotherapy on major cardiovascular (CV) events, a matched cohort study. J Clin Hypertens 2011; 13 (Suppl 1):A73.
31. Chrysant SG,Chrysant GS.Effectiveness of lowering blood pressure to prevent stroke versus to prevent coronary events. Am J Cardiol 2010; 106:825-829.